Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan vs Lansoprazole in Erosive Reflux Disease
NCT05267743Phase 4Completed
- Sponsor
- HK inno.N Corporation
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tegoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by HK inno.N Corporation. Primary endpoint: 4 weeks cumulative Erosive Reflux Disease healing rate. Started Feb 2021; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05267743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267743.